We are live on ! Find out more
IMDX

Insight Molecular Diagnostics
IMDX

65 hedge funds and large institutions have $47M invested in Insight Molecular Diagnostics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.11% less ownership

Funds ownership: 2.9% → 2.79% (-0.11%)

13% less funds holding

Funds holding: 75 → 65 (-10)

21% less capital invested

Capital invested by funds: $59.4M → $47M (-$12.3M)

57% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 23

64% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 14

Holders
65
Holders Change
-10
Holders Change %
-13.33%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
10
Reduced
23
Closed
14
Calls
$52K
Puts
–
Net Calls
+$52K
Net Calls Change
-$104K

Top Buyers

Rank Fund Capital Flow
1
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$36.4K
2
Ameriprise
Ameriprise
Minnesota
+$27.8K
3
Jane Street
Jane Street
New York
+$26.6K
4
LPL Financial
LPL Financial
California
+$26K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$18.7K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$827K
2
Millennium Management
Millennium Management
New York
-$238K
3
Citadel Advisors
Citadel Advisors
Florida
-$194K
4
SSA
Schonfeld Strategic Advisors
New York
-$180K
5
E
Ergoteles
New York
-$145K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
51
BNP Paribas Financial Markets
France
$4.58K -$6.06K -350 -53%
Royal Bank of Canada
52
Royal Bank of Canada
Ontario, Canada
$3K +$3.24K +187 +623%
Group One Trading
53
Group One Trading
Illinois
$2K -$260 -15 -10%
Osaic Holdings
54
Osaic Holdings
Arizona
$2K – – –
Federated Hermes
55
Federated Hermes
Pennsylvania
$2K +$2.1K +121 New
O
56
OrbiMed
New York
$1.37K -$827K -47,752 -34%
Citigroup
57
Citigroup
New York
$1K -$2.29K -132 -75%
Wells Fargo
58
Wells Fargo
California
$1K -$17 -1 -3%
RAM
59
Riggs Asset Management
Pennsylvania
$1K – – –
CUAMC
60
China Universal Asset Management Company
China
$1K +$970 +56 New
GCP
61
GSA Capital Partners
United Kingdom
– -$144K -8,012 Closed
Susquehanna International Group
62
Susquehanna International Group
Pennsylvania
– -$131K -7,290 Closed
Cambridge Investment Research Advisors
63
Cambridge Investment Research Advisors
Iowa
– -$33K -1,825 Closed
JF
64
Jump Financial
Illinois
– -$26K -1,457 Closed
DA
65
DCF Advisers
Connecticut
– -$23K -1,257 Closed
TSS
66
Two Sigma Securities
New York
– -$19K -1,061 Closed
CCM
67
Cinctive Capital Management
New York
– -$18K -978 Closed
EGM
68
Engineers Gate Manager
New York
– -$15K -857 Closed
HF
69
HRT Financial
New York
– -$12K -697 Closed
Fidelity Investments
70
Fidelity Investments
Massachusetts
– -$6K -304 Closed
CAPTRUST Financial Advisors
71
CAPTRUST Financial Advisors
North Carolina
– -$4K -225 Closed
New York State Common Retirement Fund
72
New York State Common Retirement Fund
New York
– -$1K -29 Closed
MAM
73
Meeder Asset Management
Ohio
– -$381 -22 -69%
1 2
3

IMDX Hedge Fund Activity: Q3 2022 in Review

65 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2022, worth a combined $47M — down 21% from $59.4M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of IMDX and 5 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 10 added.

The largest buyer was Balyasny Asset Management, adding an estimated $36.4K. The largest seller was OrbiMed, cutting an estimated $827K.

  • 65 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2022, down from 75 in Q2 2022.
  • Funds reported $47M of Insight Molecular Diagnostics stock for Q3 2022, down 21% quarter-over-quarter.
  • 5 funds opened new Insight Molecular Diagnostics positions in Q3 2022 and 14 closed out, a net change of -9 holders.
  • The largest Insight Molecular Diagnostics buyer in Q3 2022 was Balyasny Asset Management, an estimated $36.4K added.
  • The largest Insight Molecular Diagnostics seller in Q3 2022 was OrbiMed, an estimated $827K sold.

Based on aggregated 13F filings for Q3 2022.